跳到正文
原文
MedTech Dive 器械媒体· Nick Paul Taylor·· 14 天前AI 评分34

西门子健康将重组体外诊断业务并独立运营

Siemens Healthineers to rebrand and separate its IVD business

AI 导读

西门子健康计划在2028年中之前将体外诊断业务重新品牌为Olyrian Diagnostics,并独立运营。该业务将专注于实验室和现场诊断产品。西门子健康同时计划在2028年之前剥离其母公司,股东将于2月召开会议投票决定。

正文

An article from site logo

Dive Brief

The company is rebranding the unit as Olyrian Diagnostics and plans to set it up as a standalone business by mid-2028.

Published Nov. 6, 2026

By

A picture of Siemens Healthineers' headquarters building in Erlangen, Germany.

Siemens Healthineers' headquarters in Erlangen, Germany. Courtesy of Siemens Healthineers

Dive Brief:

  • Siemens Healthineers said Thursday it will rebrand its in vitro diagnostics business and establish the unit as a standalone organization by mid-2028.
  • The rebranded business, Olyrian Diagnostics, will sell diagnostics for laboratory and point-of-care testing. Clients include Quest Diagnostics, which recently extended its contract by five years.
  • Siemens Healthineers is rebranding its remaining business. Next year, the company will start a three-year transition to rebrand as Healthineers, dropping Siemens from its name. The rebrand coincides with a plan announced late last year for Siemens to give up its controlling stake in Siemens Healthineers. Shareholders will vote about the plan to spin off Siemens Healthineers shares at an annual meeting in February.

Dive Insight:

Siemens Healthineers has laid the groundwork for the carve-out of its IVD business over the past year. One year ago, the company told investors that the diagnostics business would have its own strategy. Executives revealed the planned carve-out of the diagnostics business in May. The actions reflect a belief that the business does not have a synergistic relationship with the company’s other three units. 

“We have started the carve-out with a clear intention to separate,” CEO Bernd Montag said on Siemens Healthineers’ earnings call Thursday. “This process will position diagnostics as a market-leading in vitro pure play and help diagnostics to leverage its strength across lab solutions and point-of-care testing, offering a differentiated portfolio that meets the evolving needs of healthcare systems.”

Comparable revenue at the diagnostics business fell 4.2% in fourth-quarter results published Thursday. Sales “stabilized sequentially while still declining” year over year, Montag said. Diagnostics sales in China continue to decline “due to the structural market rebasing” in the country, CFO Jochen Schmitz said on the earnings call.

Siemens Healthineers is preparing to carve out its diagnostics business while working through the split from its own parent company. Eight years after selling shares in the healthcare business, Siemens plans to spin off Healthineers. Shareholders will vote on the separation in February. Healthineers will pay Siemens 300 million euros (about $334 million) for the three-year brand transition phase. 

The healthcare business is targeting an additional 400 million euros in savings at the diagnostics unit, Schmitz said. The cost-cutting drive spans operational processes, R&D, sales and every other part of the business, and the company will realize a “significant chunk” of the savings by 2028, Schmitz said. 

Building on its cost and pricing initiatives, Siemens Healthineers is launching “additional measures to counter over 300 million euros of stranded costs stemming from the diagnostics carve-out, the focusing of ultrasound and the deconsolidation from Siemens,” Montag said.

The short-term disruption will position the company to “focus capital allocation clearly in the mid- and long-term,” Schmitz said.

来源:MedTech Dive 器械媒体 · medtechdive.com